| Literature DB >> 28431203 |
Jae Geun Lee1, Kwang-Woong Lee2, Choon Hyuck David Kwon3, Chong Woo Chu4, Bong-Wan Kim5, Dong Lak Choi6, Young Kyoung You7, Dong-Sik Kim8, Yang Won Nah9, Koo Jeong Kang10, In Soek Choi11, Hee Chul Yu12, Geun Hong13, Ho-Seong Han2, Shin Hwang14, Myoung Soo Kim1.
Abstract
Major concerns about donor safety cause controversy and limit the use of living donor liver transplantation to overcome organ shortages. The Korean Organ Transplantation Registry established a nationwide organ transplantation registration system in 2014. We reviewed the prospectively collected data of all 832 living liver donors who underwent procedures between April 2014 and December 2015. We allocated the donors to a left lobe group (n = 59) and a right lobe group (n = 773) and analyzed the relations between graft types and remaining liver volumes and complications (graded using the Clavien 5-tier grading system). The median follow-up was 19 months (range, 10-31 months). During the study period, 553 men and 279 women donated livers, and there were no deaths after living liver donation. The overall, biliary, and major complication (grade ≥ III) rates were 9.3%, 1.7%, and 1.9%, respectively. The graft types and remaining liver volume were associated with significantly different overall, biliary, and major complication rates. Of the 16 patients with major complications, 9 (56.3%) involved biliary complications (2 biliary strictures [12.5%] and 7 bile leakages [43.8%]). Among the 832 donors, the mean aspartate transaminase, alanine aminotransferase, and total bilirubin levels were 23.9 ± 8.1 IU/L, 20.9 ± 11.3 IU/L, and 0.8 ± 0.4 mg/dL, respectively, 6 months after liver donation. In conclusion, biliary complications were the most common types of major morbidity in living liver donors. Donor hepatectomy can be performed successfully with minimal and easily controlled complications. Our study shows that prospective, nationwide cohort data provide an important means of investigating the safety in living liver donation. Liver Transplantation 23 999-1006 2017 AASLD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28431203 DOI: 10.1002/lt.24778
Source DB: PubMed Journal: Liver Transpl ISSN: 1527-6465 Impact factor: 5.799